US EditionNektar Therapeutics Stock Rockets 19% on Strong 52-Week Alopecia Areata Data for Lead Drug Candidate
The company said 29% and 31% of patients in two dose groups reached new SALT20 responses after 52 weeks, supporting later-stage development.
- On Monday, April 20, 2026, Nektar Therapeutics announced 52-week results from its Phase 2b REZOLVE-AA study, demonstrating that rezpegaldesleukin promotes meaningful hair growth in patients with severe-to-very-severe alopecia areata.
- The trial evaluated rezpegaldesleukin, a first-in-class regulatory T-cell proliferator, in 92 patients globally, with participants receiving twice-monthly subcutaneous injections during the 16-week treatment extension.
- Clinical data revealed 94% of patients completed treatment, with 38.8% of high-dose patients achieving SALT50 scores by week 52 compared to 13.6% with placebo.
- Jonathan Silverberg, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences, said the data point to "the first safe and effective biologic" in alopecia areata.
- These results support Nektar's plan to advance rezpegaldesleukin into late-stage registrational trials, addressing prescribing and safety limitations of current JAK inhibitor therapies.
12 Articles
12 Articles
Nektar Therapeutics Stock Rockets 19% on Strong 52-Week Alopecia Areata Data for Lead Drug Candidate
Shares of Nektar Therapeutics surged more than 19% in early Monday trading on April 20, 2026, climbing $16.58 to $101.44 as investors cheered positive 52-week topline results from the Phase 2b
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin
29% and 31% of patients in the 18 µg/kg and 24 µg/kg extension arms, respectively, achieved new SALT Score ≤20 from week 36 to week 52 with continued...
Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026 (2026-04-19)
-Nektar Therapeutics, a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52- week topline results from the 16- week extension treatment period of the ongoing Phase 2 b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a...
Nektar’s long-term mid-stage alopecia data fuel Phase 3 plans
Nektar Therapeutics’ data from the extension phase of a failed Phase 2b alopecia trial just about met Wall Street analysts' expectations, helping the biotech’s ambitions to move forward in the indication. The company’s rezpegaldesleukin, more ...
Why Nektar Therapeutics (NKTR) Is Up 5.5% After 52-Week REZOLVE-AA Rezpegaldesleukin Data Release And What's Next
Nektar Therapeutics recently hosted an investor call to review 52-week topline results from the 16-week extension of its ongoing Phase 2b REZOLVE-AA trial of investigational rezpegaldesleukin, a regulatory T-cell proliferator for severe-to-very-severe alopecia areata, with detailed materials posted on the company’s website. This readout matters because it extends the evidence base for rezpegaldesleukin in a high-need autoimmune hair loss indicat…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
